PMV Pharmaceuticals, Inc. (PMVP) Form 10-Q — May 12, 2026
PMV Pharmaceuticals, Inc. reported a net loss of $18.0 million for the three months ended March 31, 2026, compared to a net loss of $17.4 million for the same period in 2025. The company's cash and cash equivalents as of March 31, 2026, were $39.1 million, a slight increase from $37.9 million at the end of 2025. The company's total operating expenses decreased by $2.5 million to $19.0 million for the three months ended March 31, 2026, from $21.6 million in the same period in 2025.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Total Debt
- 8595
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 96562
- Cash Position
- 39130
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 53331766
- Other Income Net
- 1
- Total Other Income
- 981
- Interest Income Net
- 980
- Total Working Capital
- 87185
- Total Operating Expenses
- 19019
- Research And Development Expenses
- 15330
- General And Administrative Expenses
- 3689
Price after filing
Close on the filing date to close N calendar days later (from $1.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.